Abiraterone Acetate is Used for the treatment of advanced prostate cancer in combination with prednisone, including metastatic castration-resistant and high-risk castration-sensitive types. It was first introduced by Janssen Biotech Inc in its drug Zytiga on Apr 28, 2011. Another drug containing Abiraterone Acetate is Yonsa. 15 different companies have introduced drugs containing Abiraterone Acetate.
Abiraterone Acetate Patents
Given below is the list of patents protecting Abiraterone Acetate, along
with the drug name that holds that patent and the company name owning that
drug.
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Abiraterone Acetate's patents.
Latest Legal Activities on Abiraterone Acetate's Patents
Given below is the list recent legal activities going on the following
patents of Abiraterone Acetate.
Activity
Date
Patent Number
Payment of Maintenance Fee, 8th Year, Large Entity
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on
Abiraterone Acetate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Several generic applications have been filed for Abiraterone Acetate. The first generic version for Abiraterone Acetate was by Apotex Inc and was approved on Oct 31, 2018. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Apr 24, 2024.
Given below is the list of companies who have filed for
Abiraterone Acetate generic, along with the locations of their manufacturing plants worldwide.
